Medicine

DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates

Pedro Cahn
Pedro Cahn

REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires
Etravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials with Pedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.

Similar Interviews

  • Shorter Anti-Viral Treatment for Hepatitis C: Less Effective Than Standard Regimen
  • Mitchell Shiffman REFERENCE: N Engl J Med 2007;357:124-34 MITCHELL SHIFFMAN, Virginia Commonwealth University, Richmond Standard anti-viral therapy for Hepatitis

  • Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety
  • HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and

  • HIV: Extra Drug Fails to Improve on Triple Therapy
  • Roy Gulick, Weill Cornell Medical College, New York Although the logic in antiretroviral HIV therapy has, for some years, been that

    Post a comment

    Subscribe to Audio Medica Podcast